
©2014 International Society on Thrombosis and HaemostasisA mutant produced by autoactivation 1139 Gruber A, Cantwell AM, Di Cera E, Hanson SR. The thrombin
mutant W215A/E217A shows safe and potent anticoagulant andantithrombotic effects in vivo. J Biol Chem 2002; 277:
27581 –4.
10 Gruber A, Marzec UM, Bush L, Di Cera E, Fernandez JA,
Berny MA, Tucker EI, McCarty OJ, Grifﬁn JH, Hanson SR.Relative antithrombotic and antihemostatic effects of protein C
activator versus low molecular weight heparin in primates. Blood
2007; 109: 3733 –40.
11 Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombr-
inck KW, Miller W, Mullins ES, Palumbo JS, Zheng X,
Esmon NL, Esmon CT, Thornton S, Becker A, Pelc LA, Di
Cera E, Wagner DD, Degen JL. The development of inﬂam-matory joint disease is attenuated in mice expressing the anti-coagulant prothrombin mutant W215A/E217A. Blood 2011;
117: 6326 –37.
12 Verbout NG, Yu X, Healy LD, Phillips KG, Tucker EI, Gruber
A, McCarty OJ, Offner H. Thrombin mutant W215A/E217A
treatment improves neurological outcome and attenuates central
nervous system damage in experimental autoimmune encephalo-myelitis. Metab Brain Dis 2014; doi: 10.1007/s11011-014-9558-8.
13 Dang QD, Guinto ER, Di Cera E. Rational engineering of activ-
ity and speciﬁcity in a serine protease. Nat Biotechnol 1997; 15:
146–9.14 Guinto ER, Caccia S, Rose T, Futterer K, Waksman G, Di Cera
E. Unexpected crucial role of residue 225 in serine proteases.Proc Natl Acad Sci USA 1999; 96: 1852 –7.
15 DiBella EE, Maurer MC, Scheraga HA. Expression and folding
of recombinant bovine prethrombin-2 and its activation to
thrombin. J Biol Chem 1995; 270: 163 –9.
16 Marino F, Pelc LA, Vogt A, Gandhi PS, Di Cera E. Engineering
thrombin for selective speciﬁcity toward protein C and PAR1.
J Biol Chem 2010; 285: 19145 –52.
17 Grifﬁn JH, Zlokovic B, Fernandez JA. Activated protein C:
potential therapy for severe sepsis, thrombosis, and stroke. Semin
Hematol 2002; 39: 197 –205.
18 Mosnier LO, Yang XV, Grifﬁn JH. Activated protein C mutant
with minimal anticoagulant activity, normal cytoprotective activ-ity, and preservation of thrombin activable ﬁbrinolysis inhibitor-
dependent cytoprotective functions. J Biol Chem 2007; 282:
33022 –33.
19 Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Baner-
jee Y, Fernandez JA, Yang XV, Riewald M, Weiler H, Ruggeri
ZM, Grifﬁn JH. Hyper-antithrombotic, non-cytoprotectiveGlu149Ala-activated protein C mutant. Blood 2009; 113: 5970 –8.
20 Pozzi N, Barranco-Medina S, Chen Z, Di Cera E. Exposure of
R169 controls protein C activation and autoactivation. Blood
2012; 120: 664
–70.
©2014 International Society on Thrombosis and Haemostasis114 D. C. Wood et al